Mr. Thomas is a serial entrepreneur having worked with startups in both California and North Carolina. He is currently President and CEO of Agile Sciences. Before joining Agile Mr. Thomas was president and CEO of Arbovax, a biotechnology company commercializing a unique and innovative platform technology that can be used to make vaccines against insect-borne viral diseases. Prior to Arbovax he was Vice President of Operations for StemCo Biomedical and before that, was Director of International Marketing for Bayer Biologicals and Vice President of Pacific Rim Operations for Becton Dickinson Biosciences. During his tenure with Becton Dickinson as Vice President for Asia Pacific he lived in Singapore for 5 years. He started his working life as a research scientist in the biochemistry department of the Wellcome Research Laboratories in the UK.
Malcolm Thomas, President and CEO
John Cavanagh, CSO and Co-Founder
Dr. Cavanagh is Professor and Chair of the Department of Biochemistry & Molecular Biology at the Brody School of Medicine, East Carolina University. He is an expert in protein structural biology and investigates the mechanisms by which bacteria are able to protect themselves and become resistant.
Dr. Cavanagh received his Ph.D. in Chemistry from the University of Cambridge in 1988. Prior to his current appointment, he has held positions as a Senior Research Associate at The Scripps Research Institute, Director of Structural Biology at the Wadsworth Center (New York State Department of Health), Associate Professor of Biomedical Sciences (SUNY), Professor of Chemistry (Purdue), William Neal Reynolds Distinguished Professor (NC State University), Assistant Vice Chancellor for Research (NC State University) and Senior Vice President of Discovery Science (RTI International). He is author or co-author of over 100 peer-reviewed research publications and co-author of the well-known textbook “Protein NMR Spectroscopy.” He has also served on numerous NIH and NSF grant review panels.
He has been awarded the Foulerton Gift & Binmore Kenner Fellowship of the Royal Society, NC State University’s Alumni Associations Outstanding Research Award and NC State University’s Entrepreneur of the Year (with Agile Sciences co-founder Christian Melander), and the Career Author Award at RTI International.
Christian Melander, Co-Founder
Dr. Melander is the George and Winifred Clark Professor in the Department of Chemistry and Biochemistry at the University of Notre Dame. His research expertise lies in the development of small molecules that disrupt bacterial protection mechanisms, specifically focusing on biofilm formation and antibiotic resistance.
Dr. Melander received a Ph.D. in Chemistry from Columbia University in 1998 and subsequently conducted postdoctoral research at Caltech and The Scripps Research Institute. He began his academic career in the department of chemistry at North Carolina State University in 2004. He was promoted to Associate Professor in 2010, Full Professor in 2013, and was named the Howard J. Schaeffer Distinguished Professor in 2014. Dr. Melander has published over 150 papers, reviews, commentaries, and book chapters, and has been awarded numerous patents. He is also a frequent reviewer for the NIH, the NSF, and various international granting agencies. He was named NCSU's entrepreneur of the year (with Agile Co-Founder Dr. Cavanagh), the Industrial Innovator of the Year from the Southeastern Region of the American Chemical Society, and a University Faculty Scholar at NCSU in addition to receiving the Sigma Xi faculty research award.
Dr. Sun is Vice President, Chemistry & Manufacturing at Crestone, Inc. an anti-infective drug discovery and development company in Boulder, Colorado. Prior to his current appointment, Dr Sun was an executive director of chemistry and CFTR modulator team leader at N30 Pharmaceuticals (Nivalis Therapeutics, merged with Alpine Immune Sciences), overseeing internal and external activities from medicinal chemistry, chemical process development, and manufacturing of multi-kilo scale active pharmaceutical ingredients under cGMP, to compound screening using enzyme and cell-based assays and selection of candidate compounds for development. Prior to this appointment, he was a Principal Scientist at Replidyne, Inc. where he was responsible for discovering novel antibacterial agents against several biological targets, including methionyl-tRNA synthetase and bacterial DNA polymerases.
Dr. Sun is an author or co-author of more than 60 scientific papers, meeting proceedings and conference presentations, and an inventor or joint-inventor of 34 issued patents, including the discovery of Telaprevir (INCIVEK), a HCV protease inhibitor approved for the treatment of HCV infection in 2011 and a number of compounds in clinical development: 1) CRS3123 (formerly REP3123), a methionyl-tRNA synthetase inhibitor completed Phase 1 clinical trials for the treatment of CDI; 2) N6022, a S-nitrosoglutathione reductase (GSNOR) inhibitor for the treatment of acute asthma and cystic fibrosis; 3) Cavosonstat (N91115), an oral GSNOR inhibitor currently in clinical trials for the treatment of COPD and asthma.
Dr. Sun received his BS, MS, and Ph.D. degrees in chemistry from the Dalian University of Technology in Dalian, China and conducted his post-doctoral research at the Swiss Federal Institute of Technology (ETH) in Zürich and University of Lausanne, Switzerland.
Dr. Weigang Wang is a Managing Director at Interstellar Capital. Prior to this, Dr. Wang spent more than 10 years with Eli Lilly and Company, and CP Pharm, where he held various leadership positions in R&D and Corporate Development. He is recognized as an expert in cancer biology, and protein therapeutics